Abstract
Background Malaria remains a major global health problem with a need for improved field-usable diagnostic tests. We have developed a portable, low-cost digital microscope scanner, capable of both brightfield and fluorescence imaging. Here, we used the instrument to digitize blood smears, and applied deep learning (DL) algorithms to detect Plasmodium falciparum parasites.
Methods Thin blood smears (n = 125) were collected from patients with microscopy-confirmed P. falciparum infections in rural Tanzania, prior to and after initiation of artemisinin-based combination therapy. The samples were stained using the 4’,6-diamidino-2-phenylindole fluorogen and digitized using the prototype microscope scanner. Two DL algorithms were trained to detect malaria parasites in the samples, and results compared to the visual assessment of both the digitized samples, and the Giemsa-stained thick smears.
Results Detection of P. falciparum parasites in the digitized thin blood smears was possible both by visual assessment and by DL-based analysis with a strong correlation in results (r = 0.99, p < 0.01). A moderately strong correlation was observed between the DL-based thin smear analysis and the visual thick smear-analysis (r = 0.74, p < 0.01). Low levels of parasites were detected by DL-based analysis on day three following treatment initiation, but a small number of fluorescent signals were detected also in microscopy-negative samples.
Conclusion Quantification of P. falciparum parasites in DAPI-stained thin smears is feasible using DL-supported, point-of-care digital microscopy, with a high correlation to visual assessment of samples. Fluorescent signals from artefacts in samples with low infection levels represented the main challenge for the digital analysis, thus highlighting the importance of minimizing sample contaminations. The proposed method could support malaria diagnostics and monitoring of treatment response through automated quantification of parasitaemia and is likely to be applicable also for diagnostics of other Plasmodium species and other infectious diseases.
Competing Interest Statement
Johan Lundin and Mikael Lundin are founders and co-owners of Aiforia Technologies Oy, Helsinki, Finland. The rest of the authors declare that there are no competing interests.
Funding Statement
This work was funded by the Swedish Research Council, Swedish International Development Agency (SIDA) and Sigrid Juselius Foundation. In addition, the study has been supported by Finska Lakaresallskapet, Biomedicum Foundation, Medicinska Understodsforeningen Liv och Halsa rf, the Nvidia Corporation and Wilhelm och Elsa Stockmanns stiftelse. We furthermore greatly acknowledge the assistance and support from the Helsinki Institute of Life Science (HiLIFE) and the FIMM Digital Microscopy and Molecular Pathology Unit supported by Helsinki University and Biocenter Finland. The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance for the study was issued by the National Institute for Medical Research and Muhimbili University of Health and Allied Sciences, Tanzania (Identifier: NCT03241901).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Corrected numerical error in S Fig 3
Data Availability
All relevant data are within the manuscript and its Supporting Information files. Further requests for sharing of de-identified data (digitized samples) will be considered from researchers abiding the following principles: data will be securely stored with appropriate documentation and not disposed into publicly accessible domains or otherwise shared without explicit permission from the authors, data is only used with the aim to generate data for the public good. Applications are subjected to review by the Data Access Committee at Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland; e-mail: fimm-dac@helsinki.fi)
